Mallinckrodt Pharmaceuticals received FDA approval for its engineered skin product, StrataGraft, a treatment for serious thermal burns. The product is the latest to be reviewed under a new designation for regenerative medicines.
Fresh off a $3 million fundraise, Stratatech Corp. plans to begin Phase 2b clinical trials of its genetically engineered human-skin substitute. The Madison, Wis.-based company said it plans to begin the trials of its StrataGraft skin substitute, which is designed for patients suffering from burns or other sever wounds, in the second half of this […]
3D medical animation services have emerged as a groundbreaking tool in the healthcare industry, revolutionizing the way medical concepts are taught, understood, and marketed.